ArticleNPJ precision oncology2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.
Open access · goldAbstract read
In one paragraph
Article in NPJ precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.International journal of cancer · 2026Article
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- Article
- Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance.Frontiers in oncology · 2026Article
- Personalized Therapy in a Patient WithJTO clinical and research reports · 2025Article
- Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.NPJ systems biology and applications · 2024Article
- ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework.NPJ precision oncology · 2024Review
- [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer.Frontiers in pharmacology · 2024Article
- Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.Frontiers in oncology · 2024Article
- Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives.Biomedicines · 2023Review
- Article
- Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.Scientific reports · 2022Article
- Characteristics of and Treatment Strategies for AdvancedJTO clinical and research reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 4 countries.
Diana Schaufler *University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
David F Ast *University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.ORCID http://orcid.org/0000-0001-6699-0754
Hannah L TumbrinkUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.
Nima AbedpourUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Lukas MaasUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Ayla E SchwäbeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.ORCID http://orcid.org/0000-0002-9435-9000
Inga SpilleUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.
Stefanie LennartzUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany.
Jana FassunkeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Mihaela AldeaDepartment of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Benjamin BesseDepartment of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
David PlanchardDepartment of medical oncology, Thoracic Group, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris, France.
Lucia NogovaUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Sebastian MichelsUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Carsten KobeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, Germany.ORCID http://orcid.org/0000-0002-2909-0826
Thorsten PersigehlUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Diagnostic and Interventional Radiology, Cologne, Germany.
Theresa WestphalUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Sophia KoleczkoUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Rieke FischerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Jan-Phillip WeberUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Janine AltmüllerCologne Center for Genomics, University of Cologne, Cologne, Germany.
Roman K ThomasUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.
Sabine Merkelbach-BruseUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.
Oliver GautschiUniversity of Bern and Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Laura MezquitaMedical Oncology Department, Hospital Clinic, Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Reinhard BüttnerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Network Genomic Medicine, Cologne, Germany.ORCID http://orcid.org/0000-0001-8806-4786
Jürgen WolfUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany.
Martin PeiferUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany.ORCID http://orcid.org/0000-0002-5243-5503
Johannes BrägelmannUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. johannes.braegelmann@uni-koeln.de.ORCID http://orcid.org/0000-0002-1306-2169
Matthias SchefflerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Network Genomic Medicine, Lung Cancer Group Cologne, Cologne, Germany. matthias.scheffler@uk-koeln.de.ORCID http://orcid.org/0000-0002-9031-1368
Martin L SosUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Pathology, Molecular Pathology, Cologne, Germany. martin.sos@uni-koeln.de.ORCID http://orcid.org/0000-0002-2868-100X
University of Cologne · DEUniversité Paris-Sud · FRGerman Cancer Research Center · DEHospital Clínic de Barcelona · ESUniversity of Bern · CH
Funding
Deutsche Krebshilfe (German Cancer Aid) 70112888Fritz Thyssen Stiftung (Fritz Thyssen Foundation) 10.19.2.025MN
Abstract
Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients. However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR therapy remains elusive. We tracked the evolution of subclonal mutations by whole-exome sequencing and performed clonal analyses of individual metastases during therapy. Complementary functional analyses of polyclonal EGFR-mutant cell pools showed a dose-dependent enrichment of BRAF
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.